Orchestra BioMed Holdings (OBIO) EBT Margin (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly EBT Margin came in at 22504.55% in Q1 2026, down 2027148.0% year-on-year from N/an in Q1 2025, and down 108933.57% on a QoQ basis from 20.68% in Q4 2025.
Orchestra BioMed Holdings (OBIO) EBT Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of EBT Margin data on file, last reported at 22504.55% in Q1 2026.
- On a quarterly basis, EBT Margin fell 2027148.0% year-over-year to 22504.55% in Q1 2026; TTM through Mar 2026 was 184.78%, a 252800.0% increase from a year earlier, with the FY2025 full-year figure at 478.1%, up 551928.0% from the prior year.
- EBT Margin for Q1 2026 stood at 22504.55%, down from 20.68% in the prior quarter.
- Over the last five years, EBT Margin for OBIO reached as high as 20.68% in Q4 2025 and fell as low as 22504.55% in Q1 2026.
- Historically, EBT Margin has averaged 3577.07% across 5 years, with a median of 2233.06% in 2025.
- Across the five-year window, EBT Margin jumped 638352 bps in 2025 and slumped 2027148 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 921.03% in 2022, then slumped by 406 bps to 4656.49% in 2023, then tumbled by 37 bps to 6362.85% in 2024, then surged by 100 bps to 20.68% in 2025, then sank by 108934 bps to 22504.55% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 22504.55% in Q1 2026, 20.68% in Q4 2025, and 2385.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -22,504.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,504.55% |
| Dec 31, 2025 | 20.68% |
| Sep 30, 2025 | -2,385.37% |
| Jun 30, 2025 | -2,579.90% |
| Mar 31, 2025 | -2,233.06% |
| Dec 31, 2024 | -6,362.85% |
| Sep 30, 2024 | -1,785.41% |
| Jun 30, 2024 | -3,237.53% |
| Mar 31, 2024 | -2,548.06% |
| Dec 31, 2023 | -4,656.49% |
| Sep 30, 2023 | -5,255.13% |
| Jun 30, 2023 | -1,853.33% |
| Mar 31, 2023 | -1,021.99% |
| Dec 31, 2022 | -921.03% |
| Sep 30, 2022 | -898.88% |
| Jun 30, 2022 | -1,967.83% |
| Mar 31, 2022 | -619.40% |